Literature DB >> 16428790

Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection.

Jennifer A Snyder1, Amanda L Lloyd, C Virginia Lockatell, David E Johnson, Harry L T Mobley.   

Abstract

Type 1 fimbrial phase-locked mutants of uropathogenic Escherichia coli cystitis isolate F11 were used to assess the role of the invertible element during urinary tract infection. Compared to the wild type, the phase-locked off mutant was attenuated, and constitutive production of type 1 fimbriae by the phase-locked on mutant did not provide a competitive advantage.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16428790      PMCID： PMC1360342          DOI： 10.1128/IAI.74.2.1387-1393.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  19 in total

1.  Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli.

Authors:  R A Welch; V Burland; G Plunkett; P Redford; P Roesch; D Rasko; E L Buckles; S-R Liou; A Boutin; J Hackett; D Stroud; G F Mayhew; D J Rose; S Zhou; D C Schwartz; N T Perna; H L T Mobley; M S Donnenberg; F R Blattner
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-05       Impact factor: 11.205

2.  An invertible element of DNA controls phase variation of type 1 fimbriae of Escherichia coli.

Authors:  J M Abraham; C S Freitag; J R Clements; B I Eisenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

3.  In vivo dynamics of type 1 fimbria regulation in uropathogenic Escherichia coli during experimental urinary tract infection.

Authors:  N W Gunther; V Lockatell; D E Johnson; H L Mobley
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Requirement of MrpH for mannose-resistant Proteus-like fimbria-mediated hemagglutination by Proteus mirabilis.

Authors:  X Li; D E Johnson; H L Mobley
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

5.  Transcriptome of uropathogenic Escherichia coli during urinary tract infection.

Authors:  Jennifer A Snyder; Brian J Haugen; Eric L Buckles; C Virginia Lockatell; David E Johnson; Michael S Donnenberg; Rodney A Welch; Harry L T Mobley
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Rapid and specific detection of Escherichia coli clonal group A by gene-specific PCR.

Authors:  James R Johnson; Krista Owens; Amee R Manges; Lee W Riley
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

7.  Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin.

Authors:  L Hagberg; I Engberg; R Freter; J Lam; S Olling; C Svanborg Edén
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

8.  Relationship of type 1 pilus expression in Escherichia coli to ascending urinary tract infections in mice.

Authors:  A J Schaeffer; W R Schwan; S J Hultgren; J L Duncan
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

9.  Assessment of virulence of uropathogenic Escherichia coli type 1 fimbrial mutants in which the invertible element is phase-locked on or off.

Authors:  Nereus W Gunther; Jennifer A Snyder; Virginia Lockatell; Ian Blomfield; David E Johnson; Harry L T Mobley
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

10.  Two regulatory fim genes, fimB and fimE, control the phase variation of type 1 fimbriae in Escherichia coli.

Authors:  P Klemm
Journal:  EMBO J       Date:  1986-06       Impact factor: 11.598
View more
  31 in total

1.  Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection.

Authors:  Maria Kostakioti; Maria Hadjifrangiskou; Corinne K Cusumano; Thomas J Hannan; James W Janetka; Scott J Hultgren
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

2.  Decreased expression of type 1 fimbriae by a pst mutant of uropathogenic Escherichia coli reduces urinary tract infection.

Authors:  Sébastien Crépin; Sébastien Houle; Marie-Ève Charbonneau; Michaël Mourez; Josée Harel; Charles M Dozois
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

Review 3.  Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Authors:  Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

4.  Evaluation of CpxRA as a Therapeutic Target for Uropathogenic Escherichia coli Infections.

Authors:  Lana Dbeibo; Julia J van Rensburg; Sara N Smith; Kate R Fortney; Dharanesh Gangaiah; Hongyu Gao; Juan Marzoa; Yunlong Liu; Harry L T Mobley; Stanley M Spinola
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

5.  complex interplay between type 1 fimbrial expression and flagellum-mediated motility of uropathogenic Escherichia coli.

Authors:  M Chelsea Lane; Amy N Simms; Harry L T Mobley
Journal:  J Bacteriol       Date:  2007-05-18       Impact factor: 3.490

6.  Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides.

Authors:  Zhenfu Han; Jerome S Pinkner; Bradley Ford; Erik Chorell; Jan M Crowley; Corinne K Cusumano; Scott Campbell; Jeffrey P Henderson; Scott J Hultgren; James W Janetka
Journal:  J Med Chem       Date:  2012-04-13       Impact factor: 7.446

Review 7.  Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.

Authors:  Laurel K Mydock-McGrane; Thomas J Hannan; James W Janetka
Journal:  Expert Opin Drug Discov       Date:  2017-06-02       Impact factor: 6.098

Review 8.  Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era.

Authors:  Maria Kostakioti; Maria Hadjifrangiskou; Scott J Hultgren
Journal:  Cold Spring Harb Perspect Med       Date:  2013-04-01       Impact factor: 6.915

9.  Role for FimH in Extraintestinal Pathogenic Escherichia coli Invasion and Translocation through the Intestinal Epithelium.

Authors:  Nina M Poole; Sabrina I Green; Anubama Rajan; Luz E Vela; Xi-Lei Zeng; Mary K Estes; Anthony W Maresso
Journal:  Infect Immun       Date:  2017-10-18       Impact factor: 3.441

10.  A conserved PapB family member, TosR, regulates expression of the uropathogenic Escherichia coli RTX nonfimbrial adhesin TosA while conserved LuxR family members TosE and TosF suppress motility.

Authors:  Michael D Engstrom; Christopher J Alteri; Harry L T Mobley
Journal:  Infect Immun       Date:  2014-06-16       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.